Reovirus infection induces apoptosis of TRAIL-resistant gastric cancer cells by down-regulation of Akt activation

International Journal of Oncology

Volumn 36, Issue 4, 2010, Pages 1023-1030

  Cho, Il Rae ^a   Koh, Sang Seok ^b   Min, Hye Jin ^b   Park, Eun Hee ^a   Srisuttee, Ratakorn ^a   Jhun, Byung Hak ^a   Kang, Chi Duk ^a   Kim, Manbok ^c   Johnston, Randal N ^d   Chung, Young Hwa ^a  

^a Pusan National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d UNIVERSITY OF CALGARY   (Canada)

Author keywords

Akt; Gastric cancer; Reovirus; TRAIL

Indexed keywords

CARRIER PROTEIN; CASPASE 8; CASPASE 9; LENTIVIRUS VECTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BID; PROTEIN KINASE B; RAS PROTEIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; WORTMANNIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SUSCEPTIBILITY; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; ENZYME ACTIVATION; HUMAN; HUMAN CELL; LENTIVIRINAE; MITOCHONDRIAL MEMBRANE POTENTIAL; NONHUMAN; PRIORITY JOURNAL; REOVIRUS; SIGNAL TRANSDUCTION; STOMACH CANCER; VIRUS INFECTION;

ANDROSTADIENES; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MITOCHONDRIA; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; REOVIRIDAE; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 77749340499     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000583     Document Type: Article

References (43)

1. Ashkenazi A and Dixit VM: Death receptors: signaling and modulation. Science 281: 1305-1308, 1998.
2. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, Chin W, Jones J, Woodward A, Le T, Smith C, Smolak P, Goodwin RG, Rauch CT, Schuh JC and Lynch DH: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 5: 157-163, 1999.
3. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995.
4. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P, Blenis J and Tschopp J: TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2: 241-243, 2000.
5. Muzio M, Stockwell BR, Stennicke HR, Salvesen GS and Dixit VM: An induced proximity model for caspase-8 activation. J Biol Chem 273: 2926-2930, 1998.
6. Boatright KM, Renatus M, Scott FL, Sperandio S, Shin H, Pedersen IM, Ricci JE, Edris WA, Sutherlin DP, Green DR and Salvesen GS: A unified model for apical caspase activation. Mol Cell 11: 529-541, 2003.
7. Nesterov A, Lu X, Johnson M, Miller GJ, Ivashchenko Y and Kraft AS: Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem 276: 10767-10774, 2001.
8. Asakuma J, Sumitomo M, Asano T, Asano T and Hayakawa M: Selective Akt inactivation and tumor necrosis actor-related apoptosis-inducing ligand sensitization of renal cancer cells by low concentrations of paclitaxel. Cancer Res 63: 1365-1370, 2003.
9. Nam SY, Jung GA, Hur GC, Chung HY, Kim WH, Seol DW and Lee BL: Upregulation of FLIP(S) by Akt, a possible inhibition mechanism of TRAIL-induced apoptosis in human gastric cancers. Cancer Sci 94: 1066-1073, 2003.
10. Zhang XD, Franco A, Myers K, Gray C, Nguyen T and Hersey P: Relation of TNF-related apoptosis-inducing ligand (TRAIL) receptor and FLICE-inhibitory protein expression to TRAIL-induced apoptosis of melanoma. Cancer Res 59: 2747-2753, 1999.
11. Mouzakiti A and Packham G: Regulation of tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in Burkitt's lymphoma cell lines. Br J Haematol 122: 61-69, 2003.
12. Kim M, Chung YH and Johnston RN: Reovirus and tumor oncolysis. J Microbiol 45: 187-192, 2007.
13. Duncan MR, Stanish SM and Cox DC: Differential sensitivity of normal and transformed human cells to reovirus infection. J Virol 28: 444-449, 1978.
14. Hashiro G, Loh PC and Yau JT: The preferential cytotoxicity of reovirus for certain transformed cell lines. Arch Virol 54: 307-315, 1977.
15. Strong JE, Coffey MC, Tang D, Sabinin P and Lee PW: The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362, 1998.
16. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, Yoon CS, Waisman DM and Lee PW: Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353, 2003.
17. Coffey MC, Strong JE, Forsyth PA and Lee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998.
18. Norman KL and Lee PW: Not all viruses are bad guys: the case for reovirus in cancer therapy. Drug Discov Today 10: 847-855, 2005.
19. Park EH, Cho IR, Srisuttee R, Min HJ, Oh MJ, Jeong YJ, Jhun BH, Johnston RN, Lee SJ, Koh SS and Chung YH: CUG2, a novel oncogene confers reoviral replication through Ras and p38 signaling pathway. Cancer Gene Ther Jan.15,2010: doi: 10.1038/cgt.2009.83.
20. Park EH, Koh SS, Srisuttee R, Cho IR, Min HJ, Jhun BH, Lee YS, Jang KL, Kim CH, Johnston RN and Chung YH: Expression of HBX, an oncoprotein of hepatitis B virus, blocks reoviral oncolysis of hepatocellular carcinoma cells. Cancer Gene Ther 16: 453-461, 2009.
21. Cho IR, Koh SS, Min HJ, Park EH, Srisuttee R, Jhun BH, Jeong SH, Yoo YH, Youn HD, Johnston RN and Chung YH: Down-regulation of HIF-1alpha by oncolytic reovirus infection indepently of VHL and p53. Cancer Gene Ther Jan.15,2010: doi: 10.1038/cgt.2009.84.
22. Stoeckel J and Hay JG: Drug evaluation: Reolysin-wild-type reovirus as a cancer therapeutic. Curr Opin Mol Ther 8: 249-260, 2006.
23. Janssen HL, Higuchi H, Abdulkarim A and Gores GJ: Hepatitis B virus enhances tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) cytotoxicity by increasing TRAIL-R1/death receptor 4 expression. J Hepatol 39: 414-420, 2003.
24. Clarke P, Meintzer SM, Spalding AC, Johnson GL and Tyler KL: Caspase 8-dependent sensitization of cancer cells to TRAIL-induced apoptosis following reovirus-infection. Oncogene 20: 6910-6919, 2001.
25. Parkin DM, Pisani P and Ferlay J: Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 54: 594-606, 1993.
26. INK4B genes in gastric carcinomas. Cancer 80: 1889-1896, 1997.
27. Yokozaki H: Molecular characteristics of eight gastric cancer cell lines established in Japan. Pathol Int 50: 767-777, 2000.
28. Park JG, Yang HK, Kim WH, Chung JK, Kang MS, Lee JH, Oh JH, Park HS, Yeo KS, Kang SH, Song SY, Kang YK, Bang YJ, Kim YH and Kim JP: Establishment and characterization of human gastric carcinoma cell lines. Int J Cancer 70: 443-449, 1997.
29. Kim M, Egan C, Alain T, Urbanski SJ, Lee PW, Forsyth PA and Johnston RN: Acquired resistance to reoviral oncolysis in Ras-transformed fibrosarcoma cells. Oncogene 26: 4124-4134, 2007.
30. Norman KL, Hirasawa K, Yang AD, Shields MA and Lee PW: Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci USA 101: 11099-11104, 2004.
31. Follenzi A, Ailles LE, Bakovic S, Geuna M and Naldini L: Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25: 217-222, 2000.
32. Dull T, Zufferey R, Kelly M, Mandel RJ, Nguyen M, Trono D and Naldini L: A third-generation lentivirus vector with a conditional packaging system. J Virol 72: 8463-8471, 1998.
33. Srivastava RK, Sollott SJ, Khan L, Hansford R, Lakatta EG and Longo DL: Bcl-2 and Bcl-X(L) block thapsigargin-induced nitric oxide generation, c-Jun NH(2)-terminal kinase activity and apoptosis. Mol Cell Biol 19: 5659-5674, 1999.
34. Alessi DR, Andjelkovic M, Caudwell B, Cron P, Morrice N, Cohen P and Hemmings BA: Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J 15: 6541-6551, 1996.
35. Cory S and Adams JM: The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2: 647-656, 2002.
36. Esposti MD: The roles of Bid. Apoptosis 7: 433-440, 2002.
37. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N and Srivastava RK: Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083, 2001.
38. Nielsen-Preiss SM, Silva SR and Gillette JM: Role of PTEN and Akt in the regulation of growth and apoptosis in human osteoblastic cells. J Cell Biochem 90: 964-975, 2003.
39. Zhang J and Lodish HF: Identification of K-ras as the major regulator for cytokine-dependent Akt activation in erythroid progenitors in vivo. Proc Natl Acad Sci USA 102: 14605-14610, 2005.
40. Clarke P, Meintzer SM, Gibson S, Widmann C, Garrington TP, Johnson GL and Tyler KL: Reovirus-induced apoptosis is mediated by TRAIL. J Virol 74: 8135-8139, 2000.
41. Keane MM, Ettenberg SA, Nau MM, Russell EK and Lipkowitz S: Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res 59: 734-741, 1999.
42. Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, Dennis PA and Lipkowitz S: Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res 61: 4892-4900, 2001.
43. Clarke P and Tyler KL: Down-regulation of cFLIP following reovirus infection sensitizes human ovarian cancer cells to TRAIL-induced apoptosis. Apoptosis 12: 211-223, 2007.